Capstone Investment Advisors
REGN icon

Capstone Investment Advisors’s Regeneron Pharmaceuticals REGN Stock Holding History

Capstone Investment Advisors’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.8M Buy
6,100
+1,800
+42% +$1.23M 0.01% 565
2026
Q1 		$3.32M Buy
4,300
+3,100
+258% +$2.37M 0.01% 510
2025
Q4 		$926K Hold
1,200
– – ﹤0.01% 895
2025
Q3 		$675K Hold
1,200
– – ﹤0.01% 1197
2025
Q2 		$630K Buy
+1,200
New +$670K ﹤0.01% 1041
2025
Q1 		– Sell
-4,000
Closed -$2.85M – 1782
2024
Q4 		$2.85M Sell
4,000
-300
-7% -$252K 0.01% 730
2024
Q3 		$4.52M Sell
4,300
-600
-12% -$668K 0.01% 488
2024
Q2 		$5.15M Buy
4,900
+3,700
+308% +$3.59M 0.02% 453
2024
Q1 		$1.15M Sell
1,200
-900
-43% -$856K ﹤0.01% 1062
2023
Q4 		$1.84M Buy
2,100
+1,500
+250% +$1.24M 0.01% 830
2023
Q3 		$494K Hold
600
– – ﹤0.01% 1332
2023
Q2 		$431K Hold
600
– – ﹤0.01% 1220
2023
Q1 		$493K Sell
600
-2,400
-80% -$1.81M ﹤0.01% 1016
2022
Q4 		$2.16M Buy
3,000
+100
+3% +$73.8K 0.02% 681
2022
Q3 		$2M Buy
2,900
+1,100
+61% +$692K 0.01% 749
2022
Q2 		$1.06M Sell
1,800
-8,200
-82% -$5.33M 0.01% 982
2022
Q1 		$6.98M Sell
10,000
-52,700
-84% -$33.3M 0.02% 589
2021
Q4 		$39.6M Sell
62,700
-4,300
-6% -$2.64M 0.07% 259
2021
Q3 		$40.5M Buy
67,000
+10,000
+18% +$6.21M 0.08% 223
2021
Q2 		$31.8M Sell
57,000
-2,100
-4% -$1.06M 0.07% 248
2021
Q1 		$28M Sell
59,100
-9,700
-14% -$4.72M 0.08% 221
2020
Q4 		$33.2M Buy
68,800
+400
+0.6% +$216K 0.11% 152
2020
Q3 		$38.3M Buy
68,400
+24,400
+55% +$14.8M 0.2% 91
2020
Q2 		$27.4M Buy
44,000
+19,200
+77% +$10.9M 0.18% 99
2020
Q1 		$12.1M Sell
24,800
-51,700
-68% -$21.3M 0.19% 107
2019
Q4 		$28.7M Buy
76,500
+21,100
+38% +$7.1M 0.16% 147
2019
Q3 		$15.4M Buy
55,400
+1,000
+2% +$296K 0.11% 186
2019
Q2 		$17M Buy
54,400
+5,200
+11% +$1.73M 0.12% 182
2019
Q1 		$20.2M Buy
49,200
+38,000
+339% +$15.6M 0.19% 121
2018
Q4 		$4.18M Buy
11,200
+3,800
+51% +$1.39M 0.05% 282
2018
Q3 		$2.99M Buy
+7,400
New +$2.82M 0.03% 352

Other funds holding REGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Capstone Investment Advisors's REGN Position: Q2 2026 in Review

Capstone Investment Advisors opened a new position in Regeneron Pharmaceuticals (REGN) in Q2 2026: 1,240 shares worth $773K. The stake represents ﹤0.01% of the portfolio and ranks #1054 among its holdings. This is a return to the name: Capstone Investment Advisors previously reported a position in REGN as recently as Q4 2025.

Capstone Investment Advisors first reported a position in REGN in Q3 2015 and has held it in 26 quarters since. The position peaked at $11.9M in Q4 2020. 1,338 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • Capstone Investment Advisors held 1,240 shares of Regeneron Pharmaceuticals worth $773K as of Q2 2026.
  • Regeneron Pharmaceuticals was a new Capstone Investment Advisors position in Q2 2026.
  • Regeneron Pharmaceuticals made up ﹤0.01% of Capstone Investment Advisors's portfolio in Q2 2026, its #1054 holding.
  • Capstone Investment Advisors first reported a position in Regeneron Pharmaceuticals in Q3 2015 and has held it in 26 quarters since.
  • Capstone Investment Advisors's Regeneron Pharmaceuticals position peaked at $11.9M in Q4 2020.
  • 1,338 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Capstone Investment Advisors's 13F filing for Q2 2026, filed 17 Aug 2026.